Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $15.43.

FULC has been the topic of a number of analyst reports. Oppenheimer dropped their target price on Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 14th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, August 1st. Bank of America raised Fulcrum Therapeutics from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $5.00 to $10.00 in a research note on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $23.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, July 10th.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $8.43 on Friday. The firm has a market capitalization of $523.96 million, a P/E ratio of -5.27 and a beta of 2.23. The stock has a 50-day simple moving average of $8.47 and a two-hundred day simple moving average of $8.36. Fulcrum Therapeutics has a fifty-two week low of $3.14 and a fifty-two week high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The firm had revenue of $80.00 million for the quarter, compared to analyst estimates of $80.00 million. During the same period last year, the company earned ($0.38) earnings per share. As a group, analysts forecast that Fulcrum Therapeutics will post -0.48 earnings per share for the current year.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently made changes to their positions in the company. National Bank of Canada FI increased its holdings in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after purchasing an additional 4,000 shares during the last quarter. Capstone Investment Advisors LLC purchased a new stake in Fulcrum Therapeutics in the 4th quarter valued at $68,000. Profund Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics in the 2nd quarter worth $68,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Fulcrum Therapeutics by 66.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock worth $112,000 after acquiring an additional 4,766 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Fulcrum Therapeutics during the 1st quarter worth $115,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.